(transmembrane subunit of HIV envelope) and gp120 (surface envelope glycoprotein of HIV) (1). Both proteins therefore present highly attractive targets for the development of antiviral agents as well as broadly neutralizing antibodies. HIV Envmediated cell fusion involves a complex series of events. gp120 first binds to CD4 and a chemokine receptor; this triggers conformational changes in the gp120-gp41 complex that lead to the insertion of the gp41 fusion peptide into the target membrane and ultimately to cell fusion (2, 3).
The first step in HIV 1 infection involves virus-cell or cell-cell fusion mediated by the viral envelope glycoproteins (Env) gp41 (transmembrane subunit of HIV envelope) and gp120 (surface envelope glycoprotein of HIV) (1) . Both proteins therefore present highly attractive targets for the development of antiviral agents as well as broadly neutralizing antibodies. HIV Envmediated cell fusion involves a complex series of events. gp120 first binds to CD4 and a chemokine receptor; this triggers conformational changes in the gp120-gp41 complex that lead to the insertion of the gp41 fusion peptide into the target membrane and ultimately to cell fusion (2, 3) .
The structure of the ectodomain of gp41 (e-gp41) in its fusogenic/post-fusogenic state has been solved by both NMR (4) and crystallography (5) (6) (7) (8) and consists of a trimer of hairpins comprising an internal parallel trimeric coiled-coil of N-terminal helices (residues 542-592 of HIV-1 Env (4)) surrounded by antiparallel C-terminal helices (residues 623-663 of HIV-1 Env (4)) (left-hand side of Fig. 1 ). The formation of the fusogenic/post-fusogenic state of e-gp41 provides the driving force for the apposition of the virus and cell membranes, thereby promoting membrane fusion (2) . Prior to the formation of the fusogenic trimer of hairpins, e-gp41 exists in a "prehairpin" intermediate state (2, 9 -12) , so-called because the C region of e-gp41 (corresponding to the C-helices in the fusogenic/postfusogenic state ) is not yet associated with the internal trimeric coiled-coil of N-helices ( Fig. 1, middle) . In the prehairpin intermediate state both the internal trimeric coiled-coil (9, 10) and the C region of e-gp41 are accessible to inhibitors (13) (14) (15) .
There are three classes of fusion inhibitors that target the prehairpin intermediate state of e-gp41 (right-hand side of Fig.  1 ). Class 1 inhibitors (shown in blue at the top right of Fig. 1 ) are directed against the internal trimeric coiled-coil of N-helices. Examples of class 1 inhibitors include peptides derived from the C-helices such as C34 (residues 628 -661 of HIV-1 Env) 2 and T20 (also referred to as DP178, residues 638 -673 of HIV-1 Env which extends 10 residues beyond the C-terminal end of the C-helix), both of which have IC 50 values in the low nanomolar range (16 -18) . T20 is currently in the final stages of , and Ala 578 of HIV-1 Env substituted by Cys, Cys, and Gly, respectively; N35 CCG -N13 is a 48-residue peptide comprising N35 CCG immediately followed by N13; N CCG -gp41 is a chimeric protein comprising N35 CCG fused onto the minimal thermostable ectodomain core of gp41: N35 CCG -N34-(L6)-C28, where L6 is a six-residue linker (SGGRGG); 6H, 20-residue non-native sequence derived from the cloning vector containing a His 6 tag. phase 3 clinical trials (19, 20) . The class 2 inhibitors (shown in red at the bottom right of Fig. 1 ) are directed against the exposed C region of e-gp41. Examples include engineered proteins such as N CCG -gp41 (13) and IQN17 (21) , both of which expose the internal trimeric coiled-coil of e-gp41 in a stable manner, and the protein 5-helix, which exposes only a single helix of the internal trimeric coiled-coil (14) . N CCG -gp41, IQN17, and 5-helix have IC 50 values in the 15-25 nM range. Finally, the class 3 inhibitors (shown in yellow, middle right of Fig. 1 ), exemplified by the construct N36
Mut(e,g) , which comprises a mutated version of the trimeric coiled-coil that can no longer interact with the C region of e-gp41, act by forming heterotrimers of the N-terminal coiled-coil (22) .
The chimeric protein N CCG -gp41 ( Fig. 2) comprises an exposed trimeric coiled-coil of N-helices (residues 546 -579 of HIV-1 Env with L576C, Q577C, and A578G mutations) that is stabilized by fusion to a minimal thermostable ectodomain of gp41 and by engineered intersubunit disulfide bonds (13) . We anticipated that antibodies raised against N CCG -gp41 could potentially target the exposed trimeric coiled-coil of N-helices in the prehairpin intermediate state of gp41 in a manner analogous to the class 1 inhibitors (13) . However, antibodies directed against N CCG -gp41 will inevitably comprise a mixture of antibodies that bind not only to the exposed trimeric coiled-coil of N-helices but also to the outer surface of the minimal thermostable ectodomain, which comprises the C-helices. To circumvent this problem, we have therefore engineered two simpler variants of N CCG -gp41 that comprise only the internal trimeric coiled-coil of e-gp41: N34 CCG and N35 CCG -N13 (Fig. 2) . We show that these two variants are also nanomolar inhibitors of HIV-1 Env-mediated cell fusion. In addition, we demonstrate that purified anti-N35 CCG -N13-specific antibodies effectively inhibit HIV-1 Env-mediated cell fusion. The IC 50 of the tight binding anti-N35 CCG -N13-specific antibody fraction is comparable with that of the broadly neutralizing, gp120 targeted, monoclonal antibody 2G12 (23, 24) , which has just entered phase I clinical trials (25) . These data indicate that the internal trimeric coiled-coil of e-gp41 is accessible to neutralizing antibodies in the prehairpin intermediate state and that N35 CCG -N13 represents a potentially suitable immunogen for the generation of therapeutic monoclonal antibodies.
EXPERIMENTAL PROCEDURES
Peptides-The C34 peptide (residues 628 -661 of HIV-1 Env), purchased from Commonwealth Biotechnologies (Richmond, VA), was synthesized on a solid phase support, purified by reverse-phase high pressure liquid chromatography (HPLC), and verified for purity by mass spectrometry and amino acid analysis. C34 bears an acetyl group at the N terminus and an amide group at the C terminus.
Generation of N34 CCG and N35 CCG -N13 Constructs-The synthesis and cloning of the chimeric protein N CCG -gp41 (Fig. 2) has been described previously (13) . N CCG -gp41 comprises the engineered construct N35 CCG -N34-(L6)-C28, where N35 CCG spans residues 546 -580 of HIV-1 Env with L576C, Q577C, and A578G mutations, N34 spans residues figure) , formed subsequent to the interaction of gp120 with CD4 and a chemokine receptor, the trimeric coiled-coil of N-helices (red) and the C-terminal region (blue) of the gp41 ectodomain are exposed. The prehairpin intermediate subsequently collapses to form a trimer of hairpins (whose structure has been solved by NMR (4) and crystallography (5-8)) bringing the target and viral membranes into apposition (left-hand side of figure) . The N-and C-helices in the trimer of hairpins comprise residues 542-592 and 623-663, respectively, of HIV-1 Env (4). There are three classes of inhibitors (right-hand side of figure) that target the prehairpin intermediate and prevent its collapse into the trimer of hairpins, thereby rendering it fusion incompetent. Class 1 shown in blue (e.g. C34 (17) and the anti-N35 CCG -N13 antibodies described in the present paper) target the exposed trimeric coiled-coil of N-helices; class 2 shown in red (e.g. N CCG -gp41 (13) and N34 CCG and N35 CCG -N13 described in the present paper) target the C region; and class 3 shown in yellow (e.g. N36
Mut(e,g) (22) ) interact with the prehairpin intermediate state to form heterotrimers.
546 -579 of HIV-1 Env, (L6) is a six-residue SGGRGG linker, and C28 spans residues 628 -655 of HIV-1 Env. The insert spanning the N35 CCG -N34-(L6)-C28 domains was isolated by restriction digestion with NdeI and BamHI enzymes, and cloned into the pET15b vector (Novagen, Madison, WI), which introduces an additional 20-residue, non-native segment (GSSHHHHHHSSGLVPRGSHM) at the N terminus containing a His 6 tag. The resulting construct 6H-N CCG -gp41 was subsequently used to generate the N34 CCG and N35 CCG -N13 constructs using the purified primers 5Ј-CTCACGGTCTGGGGCATCAAACAATG-TTGTGGCCGCTAGTCCGGCATTGTGCAACAGCAAAACAACTTACT-CGC and 5Ј-GTGCAACAGCAAAACAACTTACTGCGCGCGTAAGAA-GCGCAGCAGCACCTGTTACATTG and their complements, respectively, together with the QuikChange mutagenesis protocol (Stratagene, La Jolla, CA). The N34 CCG and N35 CCG -N13 constructs therefore also bear the 20-residue non-native His 6 tag at their N terminus. All constructs were verified by DNA sequencing and expressed in Escherichia coli BL21(DE3). The composition of all expressed proteins was confirmed by mass spectrometry. Note that N CCG -gp41 was produced either with or without a His 6 linker and termed 6H-N CCGgp41 and N CCG -gp41, respectively. N34 CCG and N35 CCG -N13 were only produced with the His 6 tag linker sequence.
Purification and Protein Folding-The cells were grown at 37°C in Luria-Bertani medium to an optical density of 0.7, induced with 2 mM isopropyl-␤-D-thiogalactoside for 4 h, and harvested by centrifugation. The trimeric, intermolecular disulfide-linked form of N CCG -gp41 was prepared exactly as described previously (13) . To produce the trimeric, intermolecular disulfide-linked forms of the N34 CCG and N35 CCG -N13, 2 gm of cells were suspended in 40 ml of 6 M guanidine hydrochloride (GnHCl), 50 mM Tris-HCl, pH 8.0, 1 mM ␤-mercaptoethanol (buffer A) and lysed by sonication, followed by centrifugation at 16,000 rpm (SS-34 rotor; Sorvall, Newtown, CT) for 30 min at 18°C. The supernatant was subjected to Ni-NTA-agarose affinity column (bed volume, 10 ml) chromatography at room temperature. The column was washed in buffer A, and bound protein was eluted in the same buffer containing 0.2 M imidazole. The protein was concentrated on a Centriprep YM-3 device (Millipore Corporation, Bedford, MA) and applied at room temperature at a flow rate of 3 ml/min to a Superdex-75 column (HiLoad, 2.6 ϫ 60 cm; Amersham Biosciences) equilibrated in 50 mM Tris-HCl, pH 8, 4 M GnHCl, 5 mM EDTA, and 5 mM dithiothreitol. The peak fractions were then subjected to reverse-phase HPLC on POROS 20 R2 resin (Applied Biosystems, Foster City, CA) using a linear gradient of 0 -60% acetonitrile/0.05% trifluoroacetic acid. The peak fractions were pooled and stored at Ϫ80°C. ϳ3.2 mg of C34 peptide (residues 628 -661 of HIV-1 Env) was dissolved in 35% acetonitrile, 0.05% trifluoroacetic acid, H 2 O containing ϳ2.2 mg of either N34 CCG or N35 CCG -N13 protein at a concentration of 0.3 mg/ml. The polypeptide mixture (N34 CCG ϩ C34 or N35 CCG -N13 ϩ C34), kept in a Slide-A-Lyzer cassette (3.5 molecular weight cutoff; Pierce), was folded by dialysis against 2 liters of 50 mM sodium formate buffer, pH 3.0, for 15 h at room temperature. The intermolecular disulfide bonds were then allowed to form by oxidation using the following dialysis scheme: 20 mM sodium phosphate, pH 6.25, for 2 h; 50 mM sodium formate, pH 3.0, for 3 h; 20 mM sodium phosphate, pH 4.25, for 15 h; and finally 50 mM sodium formate, pH 3.0, for 24 h. The N34 CCG / C34 and N35 CCG -N13/C34 complexes were concentrated to ϳ1 ml and analyzed by SDS-PAGE under nonreducing conditions to verify that N34 CCG and N35 CCG -N13 were predominantly disulfide-linked trimers. The N34 CCG /C34 and N35 CCG -N13/C34 complexes were subsequently denatured in 7.5 M GnHCl, applied on a Superdex-75 column (2.6 ϫ 60 cm; Amersham Biosciences) and fractionated under denaturing conditions in 4 M GnHCl, 50 mM sodium formate, pH 4. The peak fractions corresponding to the trimeric, disulfide-linked, N34 CCG or N35 CCG -N13 proteins, stripped of C34, were pooled, dialyzed (3.5 MWCO; Pierce) against excess 50 mM sodium formate buffer, pH 3.0, concentrated (YM-3, Millipore), and stored at 4°C.
Concentrations of all samples were determined spectrophotometrically; the calculated absorbances at 280 nm (1 cm path length) for a concentration of 1 mg/ml of N CCG -gp41, N34 CCG , N35 CCG -N15, and C34 are 2.026, 0.987, 0.786, and 2.90, respectively. The corresponding molecular masses as monomers are 11863, 6011, 7546, and 4286 Da, respectively.
FIG. 2. Design of N34 CCG and N35 CCG -N13.
A, models of N CCG -gp41 (13), N35 CCG -N13, and N34 CCG . The N34-(L6)-C28 gp41 core has been solved crystallographically (7) . The model of N CCG -gp41 was constructed by grafting N35 onto the N terminus of the crystal structure to generate a contiguous 69-residue helix comprising N35 and N34. The three intermolecular disulfide bridges formed by the two cysteines introduced at positions 576 and 577 are shown in gold, and the three subunits of the trimer are shown in red, blue, and green. The models of N35 CCG -N13 and N34 CCG are directly derived from N CCG -gp41. B, sequences of N35 CCG -N13 and N34 CCG . (Note that the expressed constructs of N35 CCG -N13 and N34 CCG contain an additional 20-residue N-terminal region with a His 6 tag; see "Experimental Procedures.") The residue numbering is that of HIV-1 Env; the engineered Cys-Cys-Gly at positions 576 -578 that have replaced the wild type Leu-Gln-Ala sequence are shown in red; N13 (residues 546 -558 of HIV-1 Env) is indicated in purple; the letters a-g indicate the positions in a helical wheel presentation.
Circular Dichroism-CD spectra of N34 CCG (10 M) and N35 CCG -N15 (8 M) were recorded in 20 mM sodium formate buffer, pH 3.0, at 25°C on a JASCO J-720 spectropolarimeter using a 0.05-cm path length cell. Quantitative evaluation of secondary structure from the CD spectrum was carried out using the program CDNN (www.bioinformatik.biochemtech.uni-halle.de/cd_spect/index.html (26) ).
Production of Antibodies and Purification of IgG-Antibodies to the intermolecular disulfide-linked 6H-N34 CCG and 6H-N35 CCG -N13 trimers were raised in rabbits using the accelerated protocol services provided by Covance (Covance Research Products, Denver, PA) (27) . 125 g of N34 CCG and 200 g of N35 CCG -N13 was used for each initial and subsequent boost injections. Enzyme-linked immunosorbent assays to estimate antibody titers and IgG affinity purifications on immobilized protein A columns were performed according to established procedures (28) . An average value of 1.7 absorbance units at 280 nm for 1 mg/ml was used to calculate the concentration of purified antibodies.
Western Blotting-Proteins, nonreduced and reduced (in the presence of ␤-mercaptoethanol), were subjected to SDS-PAGE on premade 10 -20% linear gradient Tris-Tricine gels (Invitrogen). The gels were soaked for 10 min and then transferred onto a nitrocellulose membrane (Schleicher & Schuell) in 25 mM Tris buffer, pH 8, 190 mM glycine, and 20% methanol using a mini-electrophoretic transfer apparatus (BioRad). The blots were then processed using a WesternBreeze kit, a chromogenic immunogenic system for the detection of rabbit primary antibodies (Invitrogen).
Purification of Anti-N35 CCG -N13-specific Antibodies-N35 CCG -N13 was bound to Ni-NTA-agarose via its N terminus His 6 tag as follows. 1.2-1.3 mg of N35 CCG -N13 in 15 ml of PBS, pH 6.5, was slowly dispensed into a beaker containing Ni-NTA-agarose (7.5 ml of packed volume) suspended and kept stirred in 15 ml of PBS, pH 6.5, at room temperature. The agarose was packed in a XK-26 column (Amersham Biosciences) and equilibrated in PBS, pH 6.5. 10 ml of protein A affinity chromatography-purified IgG (1.8 mg/ml) derived from rabbit antisera to N35 CCG -N13 was passed through the column at a flow rate of 0.5 ml/min. The unbound fraction was collected, and after washing the column extensively in PBS, the bound antibodies were eluted in 50 mM glycine, 0.15 M NaCl, pH 3.0. The peak fractions were immediately combined, and the pH was adjusted to 8.5 using 1 M Tris-HCl buffer, pH 9.0. The protein fraction that precipitates in the latter step was recovered by centrifugation at 3000 rpm for 15 min. The purification of antibodies from the pellet (precipitate) and supernatant (soluble) fractions was identical and conducted as follows. The pellet was solubilized and denatured in 10 ml of 6 M GnHCl, 50 mM Tris-HCl, pH 8.0. The supernatant was likewise denatured in 6 M GnHCl, 50 mM Tris-HCl, pH 8.0. The GnHCl-denatured material was passed through a fresh Ni-NTA-agarose column (packed volume, 7.5 ml) equilibrated in the same buffer. Refolding of IgG in the flow-through (ϳ15 ml) was achieved by initial dialysis against 100-fold excess of 2 M GnHCl, 50 mM Tris-HCl, pH 8.0, buffer for about 5 h at room temperature, followed by extensive dialysis against PBS, pH 7.4, at 4°C. The resulting two fractions of anti-N35 CCG -N13-specific IgG, one derived from the pellet, the other from the supernatant, were concentrated (YM-10; Pierce) and stored at Ϫ20°C. As a control, protein A affinity-purified IgG from preimmune serum was also carried through the denaturation/refolding procedure.
Cell Fusion Assay-Inhibition of HIV Env-mediated cell fusion by N34 CCG , N35 CCG -N13, N CCG -gp41, and the various antibodies was carried out as described previously (13) In terms of cytotoxicity, neither the trimeric proteins N34 CCG , N35 CCG -gp41, and N CCG -gp41 nor the antibodies directed against N35 CCG -N13 showed any deleterious effects toward cell viability over the time period (2.5 h) of the fusion assay. We also note that previous experiments with our original N CCG -gp41 construct (13) using an HIV-1 spreading assay in MT4 cells over a 25-day period indicated no evidence of cytotoxicity at a concentration of N CCG -gp41 (400 nM) at which HIV-1 spreading (as measured by reverse transcriptase activity) was completely inhibited. 3 
RESULTS AND DISCUSSION
Rationale for the Design of N34 CCG and N35 CCG -N13-We have previously shown that the chimeric protein N CCG -gp41 (Fig. 2) , which comprises an exposed, stable disulfide-linked, trimeric coiled-coil of N-helices grafted in helical phase onto the minimal thermostable core of e-gp41, inhibits HIV-1 Env-mediated cell fusion with an IC 50 value of 15-20 nM. The N CCGgp41 construct is as follows: N35 CCG -N34-L6-C28 (see "Experimental Procedures"). The exposed, disulfide-linked, internal trimeric coiled-coil of e-gp41 is formed by N35 CCG , and the minimal thermostable core of e-gp41 is formed by N34-L6-C28.
From the perspective of a potential therapeutic, the N CCGgp41 trimer suffers from being rather large (ϳ35 kDa). In terms of an immunogen, antibodies raised against N CCG -gp41 will be targeted against two distinct epitopes: namely the exposed N-helical trimeric coiled-coil and the outer surface of the minimal e-gp41 core consisting of the C-helices. Thus, polyclonal antibodies raised against N CCG -gp41 cannot be used to assess whether the internal trimeric coiled-coil represents a suitable target for neutralizing antibodies. We therefore sought to design smaller, covalently linked, soluble constructs consisting solely of the internal trimeric coiled-coil of e-gp41. To this end we engineered the two constructs N34 CCG and N35 CCG -N13 (Fig. 2) by introducing stop codons at position Ile 35 of the N35 portion and position Ile 14 of the subsequent N34 portion, respectively, into the re-engineered 6H-N CCG -gp41 construct having a His 6 tag at the N terminus (see "Experimental Procedures").
Preparation and Characterization of Disulfide-linked Trimers of the N34 CCG and N35 CCG -N13 Analogs of the Internal
Trimeric Coiled-coil of gp41-The chimeric protein N CCG -gp41 folds spontaneously into a trimer, which becomes disulfidelinked upon air oxidation. In contrast, the same procedure applied to both N34 CCG and N35 CCG -N13 yields trimers only to an extent of ϳ10%. More than 95% yield of disulfide-linked trimer of N34 CCG and N35 CCG -N13, however, can readily be obtained in a three-step procedure: N34 CCG and N35 CCG -N13 are first folded in the presence of C34 peptide (which comprises the C-helix region of the trimer of hairpins in the fusogenic/ post-fusogenic state of e-gp41). This yields a trimer of the form (N34 CCG /C34) 3 (equivalent to the ectodomain core of fusogenic/ post-fusogenic gp41) and (N35 CCG -N13/C34) 3 , as evidenced by the elution profile of the complex at pH 3.0 on a Superdex-75 column (Fig. 3A, profile shown by the red dashed line for (N34 CCG /C34) 3 ). This elution pattern is nearly the same as that for N CCG -gp41, which only forms trimers (Fig. 3A, profile shown by the black line). Intermolecular disulfide bond formation between the three chains of N34 CCG or N35 CCG -N13 in the (N34 CCG /C34) 3 or (N35 CCG /N13-C34) 3 complexes is then achieved by air oxidation, upon shifting the pH of the solution to 6.25. Finally, the N34 CCG and N35 CCG -N13 disulfide-linked trimers are stripped from the C34 peptide by denaturation in 7.5 M GnHCl followed by size exclusion column chromatography (in 4 M GnHCl) and reverse-phase HPLC (see "Experimental Procedures"). Analysis of the purified folded trimeric form of N34 CCG on a Superdex-75 column is shown by the red trace in Fig. 3A . SDS-polyacrylamide gel analysis of N34 CCG and N35 CCG -N13 subsequent to folding by dialysis against 50 mM sodium formate buffer, pH 3, is shown in Fig. 3B . Both N34 CCG and N35 CCG -N13 are completely trimeric under nonreducing conditions (Fig. 3B, lanes 3 and 5, bands labeled T2 and T3,  respectively) . Treatment of the samples with a reducing agent prior to electrophoresis clearly results in both N34 CCG and N35 CCG migrating to the position of a monomer (Fig. 3B, lanes  4 and 6, labeled M2 and M3, respectively) . CCG and N35 CCG -N13-CD spectra of disulfide-linked trimeric N34 CCG and N35 CCG -N13 are shown in Fig. 4 . Both spectra display a double minimum at 208 and 222 nm, indicative of the presence of ␣-helix. Quantitative analysis of the spectra using the neural network program CDNN (26) yields an overall helical content of 43.0 Ϯ 1.5% for N34 CCG and 51.4 Ϯ 0.9% for N35 CCG -N13. These values, however, also reflect the presence of the 20-residue His 6 tag at the N terminus that is expected to be random coil. Thus, the number of helical residues/subunit present in trimeric N34 CCG and N35 CCG -N13 is 23.7 Ϯ 0.8 and 35.5 Ϯ 0.6, respectively. The difference in the number of helical residues between N34 CCG and N35 CCG -N13 reflects the 14-residue extension of the trimeric coiled-coil in N35 CCG -N13. Assuming that the His 6 tag is random coil, these values yield percentage helicities within the e-gp41-derived regions of the N34 CCG (34 residues) and N35 CCG -N13 (48 residues) constructs of 69.7 Ϯ 2.4% for N34 CCG and 74.0 Ϯ 1.3% for N35 CCG -N13.
CD Spectra of Disulfide-linked Trimeric N34
The CD data are therefore consistent with the models of N34 CCG and N35 CCG -N13 displayed in Fig. 2A . The models, however, in Fig. 2A are depicted as fully helical. In reality, it is clear from the CD data that the N-terminal 9 -10 residues of the e-gp41 derived regions of both constructs are likely to be frayed, and in the case of N35 CCG -N13, possibly the last 1-2 C-terminal residues as well. Fig. 5 is the inhibition curve for N CCG -gp41, which has an IC 50 value of 19.3 Ϯ 1.4 nM, consistent with previous data using the same fusion assay (13) . (For reference, the IC 50 for the C34 peptide, a potent class 1 inhibitor, under the same assay conditions is 2.3 Ϯ 0.5 nM (13).) Thus, one can conclude that N35 CCG -N13 is equipotent with N CCG -gp41, and the presence of the additional N13 segment coupled with the intermolecular disulfide bridge is sufficient to stabilize the appropriate region of the trimeric coiled-coil of N-helices in N35 CCG -N13. The 5-6-fold lower inhibitory activity of N34 CCG relative to both N35 CCG -N13 and N CCG -gp41 is presumably due to its slightly lower helical content, as a consequence of fraying at the N terminus.
N34 CCG and N35 CCG -N13 Are Potent Inhibitors of HIV Envmediated Cell Fusion-N34
Polyclonal Antibodies Specific to the Internal Trimeric Coiled-coil of gp41-Polyclonal antibodies to N34 CCG and N35 CCG -N13 were raised in rabbits according to a standard protocol (27) . The estimated 50% titers (i.e. the dilution at which 50% of antigen is bound using a concentration of 1 g/ml of antigen) for antibodies directed against N34 CCG and N35 CCG -N13 were 2.8 ϫ 10 4 and 1.0 ϫ 10 5 , respectively, after 3-4 months. Sera from rabbits immunized with either N34 CCG or N35 CCG -N13 reacted strongly with disulfide-linked N CCGgp41, N34 CCG , N35 CCG -N13 trimers on Western blots (data not shown), indicating that anti-N34 CCG and anti-N35 CCG -N13 antibodies recognize the trimeric coiled-coil of N-helices. (Immunoblots using purified anti-N35 CCG -N13 antibodies are discussed below and displayed in Fig. 7B.) In contrast, the native N36 peptide (residues 546 -581 of HIV-1 Env) reacts very poorly with the polyclonal antibodies (data not shown). N36, in the absence of C34, aggregates and does not form a unique species in solution (21, 22) . This provides further evidence that the anti-N34 CCG and anti-N35 CCG -N13 antibodies are targeted mainly to the folded trimeric coiled-coil of N-helices.
Because the 50% titer for the anti-N35 CCG -N13 serum was 3-4-fold higher than that for the anti-N34 CCG serum, we chose to focus further purification on the anti-N35 CCG -N13 antibodies. The scheme employed is shown in Fig. 6 (see "Experimental Procedures" for details). Total IgG was first purified by protein A affinity chromatography (28) . Fractions of the total IgG specific to the internal trimeric coiled-coil were then obtained by affinity chromatography using a N35 CCG -N13 immobilized Ni-NTA-agarose column. After elution of the unbound fraction (which comprises 90 -95% of the total protein A purified IgG) and extensive washing with PBS, the IgG fraction bound to the immobilized N35 CCG -N13 was eluted at low pH (pH 3.0). At pH 3.0, elution of N35 CCG -N13 is also expected to occur because of protonation of the histidine residues in the His 6 tag, which therefore no longer bind nickel ions. Upon raising the pH of the peak fractions to 8.5, co-precipitation of a pool of tight binding anti-N35 CCG -N13-specific IgG and N35 CCG -N13 takes place, because of the poor solubility of N35 CCG -N13 at high pH. The distribution of IgG in the co-precipitate (pellet) and soluble (supernatant) fractions is approximately equal. The protein in the pellet fraction (harvested by centrifugation) was solubilized and denatured in 6 M GnHCl (33), passed through a column containing an excess of fresh Ni-NTA-agarose to completely remove any co-precipitated N35 CCG -N13, and refolded. IgG in the supernatant fraction was purified in exactly the same manner as the pellet fraction. The resulting purified tight (from the pellet) and weak (from the supernatant) anti-N35 CCG -N13-specific antibodies contain no residual N35 CCG -N13 as judged by SDS-PAGE (Fig. 7A) and mass spectrometry and react specifically with trimeric N CCG -gp41, N34 CCG , and N35 CCG -N13 proteins observed by Western immunoblotting analysis (Fig.  7B) . The absence of contaminating N35 CCG -N13 in the purified tight binding anti-N35 CCG -N13-specific IgG fraction was further confirmed by immunoblot analysis of the tight binding anti-N35 CCG -N13-specific IgG probed against itself (Fig. 7C) .
Effect of Purified Anti-N35 CCG -N13-specific Antibodies on HIV-1 Env-mediated Cell Fusion-At 37°C, serum from rabbits immunized against N35 CCG -N13 has no effect on HIV-1 Env mediated cell fusion in a vaccinia-virus based reporter gene assay. The purified tight binding anti-N35 CCG -N13-specific IgG, however, inhibits fusion completely at concentrations as low as 10 g/ml; the weak binding anti-N35 CCG -N13-specific IgG inhibits fusion by ϳ90% at ϳ100 g/ml. As a control, both protein A-purified preimmune IgG and preimmune IgG purified in exactly the same manner as that used for the anti- N35 CCG -N13-specific antibodies (i.e. including a GnHCl denaturation step followed by refolding) show no fusion inhibitory activity at a concentration of 100 g/ml (Fig. 8) . A quantitative comparison of the fusion inhibitory activity of the tight and weak binding anti-N35 CCG -N13-specific antibodies with that of 2G12, a broadly neutralizing monoclonal antibody directed against gp120 (23, 24) , using Env from a T tropic strain of HIV-1 (LAV) is shown in Fig. 8 . The apparent IC 50 values for the tight and weak binding anti-N35 CCG -N13-specific antibodies are ϳ0.4 and ϳ20 g/ml, respectively, compared with ϳ1.5 g/ml for 2G12. Cell fusion assays using an M tropic strain of HIV-1 were also carried out for the tight binding anti-N35 CCG -N13-specific antibodies and 2G12; inhibition of M tropic Envmediated cell fusion by both antibodies is highly effective, although the IC 50 values are increased about 4-fold relative to those obtained with T tropic Env (Table I) . These results therefore allow one to conclude that the tight binding anti-N35 CCG -N13-specific antibodies are highly potent inhibitors of HIV-1 fusion and are comparable in potency to the monoclonal antibody 2G12, which has just entered phase I clinical trials (25) .
It is worth noting that antibodies raised against the native N36 peptide, which aggregates and does not form a helical trimeric coiled-coil (21, 22) , do not inhibit HIV-1 Env-mediated cell fusion at 37°C (34) . However, these antibodies can inhibit fusion if the target and effector cells are incubated for 1-2 h at a reduced temperature (31.5°C) to prolong the lifetime of fusion intermediates prior to initiating fusion by raising the temperature to 37°C (35) . These data suggested the presence of a kinetic barrier hindering access of antibodies to the internal trimeric coiled-coil in the prehairpin intermediate state (35) . The current data with the purified anti-N35 CCG -N13-specific antibodies indicate that no such kinetic barrier exists, and the much higher degree of potency of the tight binding anti-N35 CCG -N13-specific antibodies can be attributed to their very high avidity for the folded internal trimeric coiled-coil.
Concluding Remarks-Using rational design we have engineered two soluble, covalently linked, trimeric polypeptides (N34 CCG and N35 CCG -N13) comprising only the internal trimeric coiled-coil of e-gp41. Both constructs inhibit HIV-1 Envmediated cell fusion at nanomolar concentrations, and N35 CCG -N13 has the same potency as the previously engineered chimeric protein N CCG -gp41, which comprises the internal tri- FIG. 7 . Characterization of anti-N35 CCG -N13 polyclonal antibodies. A, SDS-PAGE of GnHCl denatured and refolded IgG (3.6 g) on 10 -20% Tris-Tricine precast gel (Invitrogen). Lanes 1 and 5, nonreduced and reduced (with ␤-mercaptoethanol), respectively, protein A affinity-purified IgG from preimmune serum. Lanes 2 and 6, nonreduced and reduced, respectively, weak binding anti-N35 CCG -N13-specific IgG (fraction indicated in green in the scheme shown in Fig. 6 ). Lanes 3 and 7, nonreduced and reduced tight binding anti-N35 CCG -N13-specific IgG (fraction indicated in red in the scheme shown in Fig. 6 and 8) indicate that the monomer M3 band represents ϳ3.3% of the total (T3ϩD3ϩM3) intensity, which corresponds to a protein quantity of ϳ65 ng. B, Western blot analysis of the N CCG -gp41, N34 CCG , and N35 CCG -N13 proteins reacted with purified denatured/refolded tight binding anti-N35 CCG -N13-specific IgG (i.e. antibody shown in lanes 3 and 7 of panel A) at a 1000-fold dilution from a 3.7 mg/ml stock solution. T1, T2, and T3 denote the trimeric forms of N CCG -gp41, N34 CCG , and N35 CCG -N13 proteins, respectively. C, a Western blot of overloaded purified tight binding anti-N35 CCG -N13-specific IgG (3 g) probed against itself does not reveal the presence of any N35 CCG -N13 (left-hand lane). Control bands (T3) containing 50 and 10 ng of trimeric N35 CCG -N13 protein are also shown in the middle and right lanes, respectively. One can therefore conclude that the upper limit for any possible contaminating N35 CCG -N13 in the purified tight binding anti-N35 CCG -N13-specific antibody preparation is less than 0.5%. The samples were processed for SDS-PAGE as described in the Fig. 3 legend. meric coiled-coil grafted onto the minimal thermostable core of e-gp41. The much smaller size of N35 CCG -N13 makes it a potentially useful therapeutic agent in its own right.
Antibodies raised against N35 CCG -N13 are specifically targeted to the folded internal trimeric coiled-coil and therefore have the potential to inhibit fusion in a manner analogous to the class 1 inhibitors derived from the C-helical region of e-gp41 (Fig. 1) . Although total sera from rabbits immunized with N35 CCG -N13 do not inhibit fusion, a very potent fusion inhibitory fraction, comprising 2.5-5% of the total IgG, can be readily purified by affinity chromatography on a N35 CCG -N13 immobilized column. The tight binding anti-N35 CCG -N13-specific antibody fraction inhibits both T tropic and M tropic HIV-1 Env-mediated cell fusion at 37°C and, in a vaccinia virusbased reporter gene assay, is comparable in potency to the broadly neutralizing monoclonal antibody 2G12 directed against gp120. These results therefore indicate that the internal trimeric coiled-coil of e-gp41 is accessible to antibodies in the prehairpin intermediate state and that access is not limited by a kinetic barrier. Thus, although N35 CCG -N13 in its present state does not appear to be suitable as a vaccine, N35 CCG -N13 represents a potentially suitable immunogen for the generation of therapeutic monoclonal antibodies. In terms of an effective vaccine, it is clear that the fraction in immunized serum of tight binding antibodies directed toward the internal trimeric coiled-coil of e-gp41 needs to be dramatically increased. This could potentially be achieved by engineering multivalent versions of N35 CCG -N13.
TABLE I Comparison of inhibition of T tropic (LAV) and M tropic (SF162) HIV-1 Env-mediated cell fusion in the vaccinia virus-based reporter gene assay by the tightly binding anti-N35 CCG -N13-specific antibody fraction and the 2G12 monoclonal antibody (directed against gp120)
The remote possibility that the fusion inhibitory activity of the anti-N35 CCG -N13-specific antibodies could be due to the presence of any contaminating N35 CCG -N13 is completely excluded by the data in Fig.  7C , which place an upper limit of less than 0.5% for the percentage of any N35 CCG -N13 present in the denatured/refolded purified anti-N35 CCG -N13-specific IgG preparations. The IC 50 of N35 CCG -N13 is Ϸ16 nM (Fig. 5) , which corresponds to a concentration of Ϸ0.4 g/ml; thus, at concentrations of tight binding anti-N35 CCG -N13-specific antibody corresponding to the IC 50 values for inhibition of T tropic and M tropic Env-mediated cell fusion, the maximum upper limit of any contaminating N35 CCG -N13 is Ͻ2 and Ͻ7.5 ng/ml, respectively; at such low concentrations N35 CCG -N13 displays no fusion inhibitory activity. 
